Envista Holdings Corporation (NYSE: NVST) announced its financial results for Q1 2025, reporting sales of $617 million and core sales growth of 0.2% compared to the same period last year. Net income totaled $18 million, while adjusted EBITDA margin stood at 12.8%, aligning with the company’s expectations. Notable strength in the Equipment & Consumables segment helped offset ongoing challenges in the diagnostics and orthodontics markets, particularly in China due to Value-Based Purchasing (VBP) preparations.
Operationally, Envista highlighted gains across all three of its strategic priorities: growth, operations, and people. Growth was seen in key areas such as Consumables, Spark clear aligners, and Nobel Biocare. Operational performance was supported by the Envista Business System (EBS), improved gross margins in Spark, and strong customer service levels. On the people front, the company reported improved employee engagement and a refreshed leadership team.
Despite positive developments, net operating cash flow was $0 million, and free cash flow was negative $5 million, down from $40 million and $29 million respectively in Q1 2024. Envista repurchased 1.1 million shares for $19 million, with $231 million still authorized for repurchases.
The company reaffirmed its full-year 2025 guidance, expecting 1–3% core sales growth, ~14% adjusted EBITDA margin, and adjusted EPS between $0.95 and $1.05. Envista will discuss these results further during an investor conference call, with details available on the company’s investor relations website.
Click here to read the full press release for more information.
